Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kestra Medical Technologies (KMTS) Cash & Equivalents (2024 - 2026)

Kestra Medical Technologies (KMTS) has disclosed Cash & Equivalents for 3 consecutive years, with $291.3 million as the latest value for Q1 2026.

  • Quarterly Cash & Equivalents rose 435.99% to $291.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $291.3 million through Jan 2026, up 435.99% year-over-year, with the annual reading at $237.6 million for FY2025, 2780.29% up from the prior year.
  • Cash & Equivalents for Q1 2026 was $291.3 million at Kestra Medical Technologies, up from $175.4 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $291.3 million in Q1 2026, with the low at $8.2 million in Q2 2024.
  • Average Cash & Equivalents over 3 years is $128.9 million, with a median of $100.0 million recorded in 2024.
  • Peak annual rise in Cash & Equivalents hit 2780.29% in 2025, while the deepest fall reached 101.28% in 2025.
  • Over 3 years, Cash & Equivalents stood at $76.9 million in 2024, then skyrocketed by 128.07% to $175.4 million in 2025, then surged by 66.07% to $291.3 million in 2026.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $291.3 million, $175.4 million, and $201.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.